A new vaccine is in the works to combat whooping cough following a tragic outbreak that claimed the lives of 11 infants. This development follows a severe outbreak in Britain in 2024, characterized by patients experiencing intense coughing fits that posed significant risks to both young and elderly individuals. To prevent a recurrence of such a crisis, the government is initiating a nationwide clinical trial to create a nasal spray vaccine, which would be the first of its kind capable of eradicating whooping cough bacteria residing in the nose and throat.
Preliminary testing of the novel vaccine, known as BPZE1, indicates its effectiveness in halting the spread of the infection. While the NHS currently offers an injectable vaccine to pregnant women to safeguard unborn babies, it does not prevent carriers from spreading the bacteria.
Whooping cough is highly contagious, with approximately 15,000 cases reported in England in 2024, a significant increase from 856 cases the previous year. The outbreak in the previous year led to the tragic deaths of 11 infants. Additionally, 11 fatalities were recorded among older individuals, primarily aged over 60 and with multiple documented causes of death.
Individuals infected with whooping cough remain contagious for up to three weeks after the onset of coughing. Symptoms initially resemble a common cold, such as a runny nose and sore throat, but progress to prolonged coughing spells, particularly worsening at night.
Infants may exhibit a distinctive “whoop” sound, a gasping for breath between coughs, although some adults and young babies may not produce this sound, complicating the condition’s identification.
The hallmark symptom of whooping cough is violent coughing, with episodes lasting several minutes and potentially leading to vomiting or facial redness. While the severity of whooping cough is lower in older children and adults, coughing can result in issues like sore ribs, hernias, ear infections, and stress incontinence.
In severe cases, breathing difficulties pose a significant threat, with infants at risk of respiratory failure. Babies under 12 months infected with whooping cough face heightened risks of dehydration, breathing problems, pneumonia, and seizures.
Following the significant whooping cough outbreak in 2024, infection rates have notably decreased this year. According to NHS England data, there were 896 reported cases between January and June, a stark contrast to the 15,153 cases in the corresponding period of the previous year.
The Champion-1 study for the vaccine, developed by ILiAD Biotechnologies, involved 53 adults and was published in The Lancet Microbe journal. Pending confirmation in further trials and regulatory approval, the new vaccine could be administered to both adults and children.
Supported by the National Institute for Health and Care Research (NIHR), funded by the Department of Health and Social Care, the trial represents a significant advancement in preventing the colonization of whooping cough bacteria in the nose and throat. Professor Robert Read, leading the study at the NIHR Southampton Biomedical Research Centre, expressed optimism about the potential impact of the vaccine in curbing the disease’s transmission.